Navigation Links
Study shows positive findings in treating patients with advanced hepatitis C
Date:4/24/2008

tients. Those who do not respond and have cirrhosis are at far greater risk for developing liver cancer or liver failure, so the development of treatment strategies for these nonresponders is a priority.

Conducted at approximately 40 sites in the United States, the COPILOT study compared weight-based low-dose peginterferon alfa-2b (subcutaneous injection of 0.5 mcg/kg/wk, one-third the dose used in standard HCV combination therapy) versus colchicine (0.6 mg orally, twice daily), an anti-inflammatory and antifibrotic medication, in 555 chronic hepatitis C patients with advanced liver fibrosis who previously failed interferon-based therapies. Patient baseline characteristics were well balanced between the two study arms. Over the four years of the randomized study, investigators monitored the patients to determine how many reached a primary endpoint, defined as death, liver transplant, hepatocellular carcinoma (liver cancer), variceal bleeding, or liver failure (increase in Child-Pugh-Turcotte [CPT] by 2 points with ascites, jaundice or encephalopathy). They analyzed their findings for all 555 patients, who received at least one dose of their assigned drug, in two ways: based on all events that occurred during the entire four years of the study, regardless of whether a patient was still taking their assigned drug or not (the intent-to-treat or ITT analysis), and based on only the events that occurred while patients were taking their assigned drug (the on drug analysis).

The investigators found a primary endpoint was reached by 17.8% (51/286) of patients in the peginterferon alfa-2b group versus 20.4% (55/269) in the colchicine group in the ITT analysis, and by 12.2% (35/286) and 16.0% (43/269) patients, respectively, in the on-drug analysis (treatment differences were not statistically significant). Among patients who had portal hypertension (42.3% and 48.0% of patients in the peginterferon alfa-2b and colchicine groups, respectively), peginterfero
'/>"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Study finds racial disparities in smoking cessation treatment
2. Antipodean Pharmaceuticals Announces Results of Phase 2 Study of Lead Compound MitoQ(R)
3. Harvard Business School Publishes a Case Study on Robert Wessman and Actavis
4. Study finds that competency in colonoscopy requires experience with 150 cases or more
5. Study finds cisplatin less effective than standard treatment for patients with anal cancer
6. Potential viral therapy weapon for difficult cancers is safe and effective in study
7. Study: Counseling trauma victims causes secondary trauma
8. Rat study suggests why teens get hooked on cocaine more easily than adults
9. Study Shows Increased Out-of-Pocket Expenses May Negatively Influence Initiation of TNF Blocker Therapy
10. Teenage suicides: Study advocates greater family support
11. Cancer cells spread by releasing bubbles, according to an MUHC study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014 A simplified anesthesia procedure may ... the cause of airway obstruction in patients with severe ... Analgesia . , Dr. Joshua H. Atkins and Dr. ... their colleagues have developed a new "ramp control" anesthetic ... show the "obstructive anatomy" responsible for sleep apnea. The ...
(Date:7/29/2014)... CRN International has promoted a longtime executive ... Upton, an 11-year veteran at the radio marketing company, ... managing the day-to-day execution of all CRN client campaigns. ... all activities for CRN clients, which include some ... The department interfaces directly with clients, sets project timelines ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 1WorldSync ... world’s leading healthcare suppliers will utilize the Global ... product information network to share product information with ... other trading partners across their global supply chain. ... ID at B. Braun: "B. Braun serves customers ...
(Date:7/29/2014)... July 29, 2014 The Affordable Care ... model of all hospitals. Studies show that over 400 ... simple, easy, low cost tool that great hospitals use ... 20 to 25%. , Their secret? Debriefing - the ... at the end of an operational event. Debriefing is ...
(Date:7/29/2014)... Kathleen Doheny HealthDay Reporter , ... low risk of cardiovascular disease may be able to take ... without harming their hearts, according to a new study. ... hormone replacement therapy had harmful effects on the heart. But, ... hormone treatments, and much further past menopause. In ...
Breaking Medicine News(10 mins):Health News:New anesthesia technique helps show cause of obstruction in sleep apnea 2Health News:New anesthesia technique helps show cause of obstruction in sleep apnea 3Health News:CRN International Names New Director to Lead Client Services Department 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 3Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 2Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 3Health News:Early Hormone Therapy May Be Safe for Women's Hearts 2Health News:Early Hormone Therapy May Be Safe for Women's Hearts 3
... the development of muscles.Da-Zhi Wang and other researchers of the ... the genes are among a recently discovered group of genes ... in the past few years have they been recognised as ... study authors said in an article that appeared in the ...
... experience with China, Pakistani pharmaceutical companies are keen to ... government // to relax the stringent visa norms. ... raw materials provided by the Chinese, apart from the ... problems with the Chinese, though their rates are cheaper ...
... Research Center has reported that maintaining the current recommended ... of cardiovascular disease. The researcher has asked the ... patients less than the recommended levels by aggressive blood ... is used to monitor the average amount of blood ...
... Baruch College has reported in his recent article that having ... . Dr. Brind has compiled data from recent studies of ... American Physicians and Surgeons. ,Professor Brind, ... that pregnancies leading to miscarriage or induced abortions does not ...
... obese people are in increased risk of developing eye ... Belkin and Zohar Habot-Wilner // , Goldschleger Eye Institute, ... and found that risk of developing eye problems are ... link between obesity and other chronic diseases and cancers. ...
... cholesterol can do to people. High-fat diets cause many patients' ... // to know what they consume. ,Now, new rules ... avoid trans fats, which plug arteries, and have been linked ... ,Trans fats are a result of manufacturers adding ...
Cached Medicine News:Health News:Pakistan drug companies seek trade ties with India 2Health News:Food labels to include information on trans fats in US 2Health News:Food labels to include information on trans fats in US 3
(Date:7/28/2014)... , July 28, 2014 STAAR Surgical Company ... and marketer of implantable lenses and delivery systems for ... quarter results and conference call with investors to July ... 2014.  The Company rescheduled the release date and conference ... services for Hideo Watanabe , President of STAAR ...
(Date:7/28/2014)... 2014 Reportbuyer.com has added a new market ... 2014-2018 https://www.reportbuyer.com/product/2225723/Global-Bone-Densitometers-Market-2014-2018.html ... a special type of X-ray test used to measure ... primarily to detect osteopenia or osteoporosis, diseases in which ... fractures is high. The purpose of bone densitometry is ...
(Date:7/28/2014)... -- June 28 th , 2014 – Oncolab, the ... cancer test, is making its AACC debut (booth #4051) at ... is a serum-based in vitro immunoassay, has been run for ... in the fight against cancer recurrence. Photo - ... million cancer survivors in the US alone, the race is ...
Breaking Medicine Technology:STAAR Surgical Moves Second Quarter Earnings Release and Conference Call One Day to July 31 2Global Bone Densitometers Market 2014-2018 2Global Bone Densitometers Market 2014-2018 3Global Bone Densitometers Market 2014-2018 4Global Bone Densitometers Market 2014-2018 5Oncolab, Inc. Exhibits Pioneering AMAS Cancer Test at AACC 2
... - Amgen,(Nasdaq:AMGN) today presented the results from a ... safety of Aranesp(R) (darbepoetin alfa) for the,treatment of ... or radiotherapy ("the 103 study"). Aranesp is not,approved ... these patients. These,results were presented in an oral ...
... therapeutic approach for the treatment,of early and metastatic ... - AEterna,Zentaris Inc. , a global, pure play ... presented an,abstract outlining in vivo data for its ... at the American,Association for Cancer Research (AACR) Annual ...
Cached Medicine Technology:Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 2Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 3Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 4Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 5Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 6Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 7AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 2AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 3
... The Leica MS2 is designed to perfectly ... as multidisciplinary use. The Leica MS2 combines ... M500 N with a innovative stand concept ... brakes, patented ABC balancing system for the ...
... loupes are quality surgical loupes featuring ... the healthcare professional a larger field ... field. Each set of SheerVision Loupes ... wooden box and includes side shields, ...
Surgical Loupes...
... The 1.5T Magnetom Sonata is a system ... research system and for cardiovascular and neuroradiological ... supported by previously stored optimized sequences, clinical ... is the fastest MR system in the ...
Medicine Products: